Navigation Links
New Industry Research Identifies "Operational Gap" in Clinical Trial Portfolio Management
Date:1/23/2010

76% Of Respondents Under Increasing Pressure To Improve Portfolio Management Efficiency -- Yet 87% Say They Lack Visibility To The Metrics Necessary To Achieve These Gains

Chicago, IL (PRWEB) January 22, 2010 -- ClearTrial (www.cleartrial.com), the leading provider of Clinical Trial Operations (CTO) software, today announced the results of a research study which assesses shifts in the demands on the portfolio management function at biopharmaceutical companies. The first phase of the two-part study that surveyed senior managers in portfolio management, corporate strategy, and clinical operations is available through the ClearTrial website at www.cleartrial.com/research/gap.

The study revealed the existence of a significant "operational gap" between long-range planning and project-level metrics – a gap that hampers informed decision-making. Fully 76% of survey respondents said they are under increasing pressure to improve portfolio management efficiency, yet 87% of those surveyed complained that they lack visibility to key project-level operational metrics for use in long-range planning and for proactively shifting portfolio direction.

Further defining the challenge the industry faces in long-range planning, two years ago only 7% of respondents had to manage to a 5% acceptable variance on their portfolio budget. Today that number has climbed to 33% of respondents, with 67% now needing to stay within 10% of target.

"You can’t fix what you can’t see," observed ClearTrial CEO Mike Soenen in assessing these findings. "How do companies expect to bring portfolio budgets within 5% or 10% variance if they don't have visibility to the activities that drive that variance? This inability to roll up study-level operational forecasts into the portfolio forecast means that companies are not working with current information -- and will only increase the margin of error in long-range planning."

Key findings from the research study support this contention:

 
  • 64% of respondents lacked confidence in their one-year horizon of project timelines. Yet, meeting timelines was listed as the #1 measurement of portfolio management performance.
  • 60% of respondents lacked confidence in their one-year portfolio budgets – yet budget accuracy was listed as the #2 measuring stick for portfolio management performance.
  • 57% of respondents lacked confidence in their one-year portfolio capacity forecasts – a critical issue impacting timelines as it becomes ever more challenging to have the right personnel available at the right times during the course of a study.

"Not surprisingly, the majority of those surveyed said that the pressure to improve portfolio efficiencies was increasing, and 90% of them expected that pressure to increase further next year ," added Soenen. "Without the proper processes and systems in place to close this operational gap in portfolio planning, however, the industry will continue to struggle with long-range planning efficiency."

The first part of the research study gathered metrics on the state of current portfolio management practice and challenges. The second phase of the research – scheduled for release in March 2010 – will explore portfolio management best practices that address these challenges.

About ClearTrial®
ClearTrial is the leading provider of Clinical Trial Operations (CTO) software, linking clinical planning, forecasting, and tracking of operational and financial performance in a single, integrated system. ClearTrial’s award-winning software helps life sciences companies streamline their clinical operations from Plan to Payment™ without sacrificing quality of results, providing executives and functional leaders in clinical operations, resource planning, finance, outsourcing, and project management with a common platform that promotes speed, accuracy, and consistency throughout the organization. For more information please visit http://www.cleartrial.com.

ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.

For more information contact:

Mike Lange
ClearTrial
+1 630.986.9800 x112

# # #

Read the full story at http://www.prweb.com/releases/2010/01/prweb3492184.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
2. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
3. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
4. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
5. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
6. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
7. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
8. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
9. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
10. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
11. Suntech to Attend Upcoming Investor Conferences and Industry Events
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Industry Research Identifies "Operational Gap" in Clinical Trial Portfolio Management 
(Date:6/23/2016)... ... June 23, 2016 , ... ... announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The ... is proud to add Target to its list of well-respected retailers. This list ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):